115 related articles for article (PubMed ID: 32213152)
1. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
2. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
Nicolau LAD; Nolêto IRSG; Medeiros JVR
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
[No Abstract] [Full Text] [Related]
3. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
4. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Riva L; Yuan S; Yin X; Martin-Sancho L; Matsunaga N; Pache L; Burgstaller-Muehlbacher S; De Jesus PD; Teriete P; Hull MV; Chang MW; Chan JF; Cao J; Poon VK; Herbert KM; Cheng K; Nguyen TH; Rubanov A; Pu Y; Nguyen C; Choi A; Rathnasinghe R; Schotsaert M; Miorin L; Dejosez M; Zwaka TP; Sit KY; Martinez-Sobrido L; Liu WC; White KM; Chapman ME; Lendy EK; Glynne RJ; Albrecht R; Ruppin E; Mesecar AD; Johnson JR; Benner C; Sun R; Schultz PG; Su AI; García-Sastre A; Chatterjee AK; Yuen KY; Chanda SK
Nature; 2020 Oct; 586(7827):113-119. PubMed ID: 32707573
[TBL] [Abstract][Full Text] [Related]
5. Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Zhou H; Fang Y; Xu T; Ni WJ; Shen AZ; Meng XM
Br J Pharmacol; 2020 Jul; 177(14):3147-3161. PubMed ID: 32368792
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment options for COVID-19.
Delang L; Neyts J
Eur Heart J Acute Cardiovasc Care; 2020 Apr; 9(3):209-214. PubMed ID: 32363880
[TBL] [Abstract][Full Text] [Related]
7. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z
Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.
Cao YC; Deng QX; Dai SX
Travel Med Infect Dis; 2020; 35():101647. PubMed ID: 32247927
[TBL] [Abstract][Full Text] [Related]
9. Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?
Adil MS; Narayanan SP; Somanath PR
Drug Discov Ther; 2020 Nov; 14(5):256-258. PubMed ID: 33116037
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
Magro G
Travel Med Infect Dis; 2020; 37():101685. PubMed ID: 32334088
[No Abstract] [Full Text] [Related]
11. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
Dobrovolny HM
Virology; 2020 Nov; 550():61-69. PubMed ID: 32882638
[TBL] [Abstract][Full Text] [Related]
12. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Cava C; Bertoli G; Castiglioni I
BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.
Kong Q; Wu Y; Gu Y; Lv Q; Qi F; Gong S; Chen X
Biomed Pharmacother; 2020 Aug; 128():110316. PubMed ID: 32505821
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer.
Chakravarty D; Nair SS; Hammouda N; Ratnani P; Gharib Y; Wagaskar V; Mohamed N; Lundon D; Dovey Z; Kyprianou N; Tewari AK
Commun Biol; 2020 Jul; 3(1):374. PubMed ID: 32641750
[TBL] [Abstract][Full Text] [Related]
15. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.
Coppola M; Mondola R
Drug Res (Stuttg); 2020 Jun; 70(6):286. PubMed ID: 32428941
[No Abstract] [Full Text] [Related]
16. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19.
Ortiz-Martínez Y
Travel Med Infect Dis; 2020; 37():101678. PubMed ID: 32325121
[No Abstract] [Full Text] [Related]
17. The clinical manifestations and management of COVID-19-related liver injury.
Su TH; Kao JH
J Formos Med Assoc; 2020 Jun; 119(6):1016-1018. PubMed ID: 32345544
[No Abstract] [Full Text] [Related]
18. Intensive care during the 2019-coronavirus epidemic.
González-Castro A; Escudero-Acha P; Peñasco Y; Leizaola O; Martínez de Pinillos Sánchez V; García de Lorenzo A
Med Intensiva (Engl Ed); 2020; 44(6):351-362. PubMed ID: 32362424
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.
Cho J; Lee YJ; Kim JH; Kim SI; Kim SS; Choi BS; Choi JH
Sci Rep; 2020 Oct; 10(1):16200. PubMed ID: 33004837
[TBL] [Abstract][Full Text] [Related]
20. Just the facts: What drugs are safe and effective for COVID-19?
Long B; Liang SY; Rosenberg H; Hicks C; Gottlieb M
CJEM; 2020 Sep; 22(5):591-594. PubMed ID: 32438948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
